BMS-309403
Based on 29 publication(s) in Google Scholar
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.91%
- CAS No.: 300657-03-8
- 화학식: C31H26N2O3
- 분자량:474.55
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) BMS-309403
More- Bone Res. 2022 Jun 22;10(1):45. [Abstract]
- Nat Commun. 2026 May 11;17(1):4190. [Abstract]
- Cell Death Dis. 2019 May 16;10(6):382. [Abstract]
- Cancer Lett. 2023 Oct 28:575:216403. [Abstract]
- Int J Biol Sci. 2021 Oct 11;17(15):4207-4222. [Abstract]
- Antioxidants (Basel). 2022 Dec 29;12(1):74. [Abstract]
- Free Radic Biol Med. 2022 Aug 20:189:42-57. [Abstract]
- Clin Transl Med. 2026 Feb;16(2):e70607. [Abstract]
- Clin Transl Med. 2026 Jan;16(1):e70563. [Abstract]
- EMBO Mol Med. 2025 Aug 4. [Abstract]
- J Med Chem. 2025 Jun 12;68(11):11127-11148. [Abstract]
- Biochem Pharmacol. 2025 Jul 11:241:117152. [Abstract]
- Cell Mol Life Sci. 2024 Feb 10;81(1):83. [Abstract]
- Oncogenesis. 2026 Feb 6;15(1):9. [Abstract]
- Cancer Immunol Immunother. 2026 Apr 15;75(5):145. [Abstract]
- Eur J Pharmacol. 2026 May 30:1030:179061. [Abstract]
- Int Immunopharmacol. 2023 Sep 2;124(Pt A):110859. [Abstract]
- Mol Neurobiol. 2025 Nov 21;63(1):130. [Abstract]
- BMC Chem. 2025 Sep 30;19(1):270. [Abstract]
- Indian J Dermatol Venereol Leprol. 2025 Jul 4:1-13. [Abstract]
- Food Chem Toxicol. 2025 Apr 2:115428. [Abstract]
- Iran J Basic Med Sci. 2022 Oct;25(10):1260-1266. [Abstract]
- Br J Nutr. 2022 Jan 14;127(1):3-11. [Abstract]
- J Proteomics. 2020 Feb 10;212:103570. [Abstract]
- Am J Cancer Res. 2019 Oct 1;9(10):2140-2155. [Abstract]
- Comp Biochem Physiol B Biochem Mol Biol. 2022 Apr-May:259:110715. [Abstract]
- Neurosci Lett. 2025 Mar 28:853:138199. [Abstract]
- Parasitol Res. 2019 Jun;118(6):1919-1926. [Abstract]
- Res Sq. 2026 Jun 15.
-
In Vivo Efficacy Study
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
Histological Imaging/Staining
-
Histological Imaging/Staining
Biological Activity
Ki: less than 2 nM (FABP4), 250 nM (FABP3), 350 nM (FABP5)[1]
Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (ApoE−/− mice)[3]
-
Dosage:15 mg/kg
-
Administration:Chronic treatment ; daily for 6 weeks
-
Result:Significantly increased the phosphorylated eNOS (Ser1177) and total eNOS but not the phosphorylated to total eNOS ratio in aortae of 18 weeks old ApoE−/− mice.
Chemical Information
-
CAS No. 300657-03-8
-
Appearance Solid
-
분자량 474.55
-
화학식 C31H26N2O3
-
Color White to off-white
-
SMILES
O=C(O)COC1=CC(C2=CC=CC=C2N3N=C(C4=CC=CC=C4)C(C5=CC=CC=C5)=C3CC)=CC=C1
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (29)
-
Journal Impact Factor
-
Most Recent
-
Bone Res
FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. [Abstract]2022 Jun 22;10(1):45. PMID: 35729106
BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]
The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), rhFABP4 (P), rhFABP4 + BMS309403 (20 μmol/L, 1h) (PB). Scale bar: 100 µm.
BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]
The effect of FABP4 and M1-polarized macrophage supernatant on HUVECs, FLSs, and chondrocytes in vitro. Tube formation assay and quantification of HUVECs cultured with vehicle (C), M1-polarized macrophage supernatant (S), or M1-polarized macrophage supernatant+BMS309403 (20 μmol/L, 1h) (SB) (n = 3 per group). Scale bar: 100 µm.
BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]
Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 4 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.
BMS-309403 purchased from MedChemExpress. Usage Cited in: Bone Res. 2022 Jun 22;10(1):45. [Abstract]
Representative images and quantification of FABP4 immunohistochemical staining and coimmunostaining of FABP4 with F4/80 or NOS2 in the synovium of TSC1KO mice treated with vehicle, BMS309403 (5 mg/kg, ip, twice a week) or anagliptin for 8 weeks after AIA modeling (n = 10 per group). Scale bar: 12.5 µm and 100 µm.
-
Nat Commun
Ascites protects against ferroptosis and enables the peritoneal growth of ovarian cancer. [Abstract]2026 May 11;17(1):4190. PMID: 42115216 -
Cell Death Dis
FABP4 contributes to renal interstitial fibrosis via mediating inflammation and lipid metabolism. [Abstract]2019 May 16;10(6):382. PMID: 31097687 -
Cancer Lett
FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. [Abstract]2023 Oct 28:575:216403. PMID: 37741433
BMS-309403 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Oct 28:575:216403. [Abstract]
STAM mice were treated with small-molecule inhibitors targeting LPL (Orlistat, S+O), FABP4 (BMS309403 (15 mg/kg, ip, twice a week), S+B), or CPT1 (Etomoxir, S+E). Tumor burden was reduced in all inhibitor-treated groups compared to the STAM control group.
-
Int J Biol Sci
Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. [Abstract]2021 Oct 11;17(15):4207-4222. PMID: 34803493 -
Antioxidants (Basel)
Genipin Attenuates Diabetic Cognitive Impairment by Reducing Lipid Accumulation and Promoting Mitochondrial Fusion via FABP4/Mfn1 Signaling in Microglia. [Abstract]2022 Dec 29;12(1):74. PMID: 36670935 -
Free Radic Biol Med
Loss of EMP1 promotes the metastasis of human bladder cancer cells by promoting migration and conferring resistance to ferroptosis through activation of PPAR gamma signaling. [Abstract]2022 Aug 20:189:42-57. PMID: 35850179 -
Clin Transl Med
Adipocyte fatty acid-binding protein as a cerebrospinal fluid-accessible biomarker and druggable target in subarachnoid haemorrhage: Linking fatty acid dysregulation to microglial neuroinflammation. [Abstract]2026 Feb;16(2):e70607. PMID: 41612866 -
Clin Transl Med
FABP4-mediated lipid droplet accumulation drives epithelial-mesenchymal transition and aggravates alveolar epithelial barrier disruption. [Abstract]2026 Jan;16(1):e70563. PMID: 41454478 -
EMBO Mol Med
Saturated fatty acids induce lipotoxicity in lymphatic endothelial cells contributing to secondary lymphedema development. [Abstract]2025 Aug 4. PMID: 40759794 -
J Med Chem
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity. [Abstract]2025 Jun 12;68(11):11127-11148. PMID: 40387207 -
Biochem Pharmacol
Rhein suppresses osteosarcoma progression via modulating the miR-328-3p/TCF7L2/FABP4 axis. [Abstract]2025 Jul 11:241:117152. PMID: 40653025 -
Cell Mol Life Sci
Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia-reperfusion injury in steatotic liver transplantation. [Abstract]2024 Feb 10;81(1):83. PMID: 38341383 -
Oncogenesis
Fatty acid uptake mediated by FABP4 promotes the formation of CD8+T cell senescence through lipid peroxidation in the adipocyte-rich microenvironment of Ovarian Cancer. [Abstract]2026 Feb 6;15(1):9. PMID: 41651808 -
Cancer Immunol Immunother
Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cancer. [Abstract]2026 Apr 15;75(5):145. PMID: 41984099 -
Eur J Pharmacol
Pharmacological inhibition of fatty acid-binding protein 4 alleviates sepsis-associated acute kidney injury in mice via suppressing ferroptosis. [Abstract]2026 May 30:1030:179061. PMID: 42219054 -
Int Immunopharmacol
Interleukin-10 increases macrophage-mediated chemotherapy resistance via FABP5 signaling in multiple myeloma. [Abstract]2023 Sep 2;124(Pt A):110859. PMID: 37666065 -
Mol Neurobiol
Fatty Acid-binding Protein 4 Exacerbates Blood-brain Barrier Disruption Through the JNK/c-Jun/MMP12 Pathway After Traumatic Brain Injury. [Abstract]2025 Nov 21;63(1):130. PMID: 41269411 -
BMC Chem
Discovery of novel FABP1 inhibitors for the treatment of metabolic dysfunction-associated steatohepatitis and hepatic fibrosis. [Abstract]2025 Sep 30;19(1):270. PMID: 41029781 -
Indian J Dermatol Venereol Leprol
FABP5 reprograms lipid metabolism and promotes cutaneous T-cell lymphoma progression via activation of PPARγ signalling. [Abstract]2025 Jul 4:1-13. PMID: 40826877 -
Food Chem Toxicol
Inhibiting fatty acid-binding protein 4 reverses inflammation and apoptosis in wasp sting-induced acute kidney injury. [Abstract]2025 Apr 2:115428. PMID: 40185302 -
Iran J Basic Med Sci
Inhibition of FABP4 attenuates cardiac fibrosis through inhibition of NLRP3 inflammasome activation. [Abstract]2022 Oct;25(10):1260-1266. PMID: 36311201 -
Br J Nutr
PPARγ regulates fabp4 expression to increase DHA content in golden pompano ( Trachinotus ovatus) hepatocytes. [Abstract]2022 Jan 14;127(1):3-11. PMID: 33663633 -
J Proteomics
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics. [Abstract]2020 Feb 10;212:103570. PMID: 31706944 -
Am J Cancer Res
25-HC promotes hepatocellular carcinoma metastasis through up-regulation of TLR4 dependent FABP4. [Abstract]2019 Oct 1;9(10):2140-2155. PMID: 31720079
BMS-309403 purchased from MedChemExpress. Usage Cited in: Am J Cancer Res. 2019 Oct 1;9(10):2140-2155. [Abstract]
FABP4 expression is up-regulated in the metastatic tumor sites. BALB/C nude mice are intrahepatic inoculation of 5 × 106 HepG2 cells followed by intraperitoneally injection with PBS or 25-HC (10 mg/kg) or 25-HC with BMS-309403 (45 mg/kg). At the end of the experiment, mice are sacrificed, the tumor tissues in the livers of the mice without metastasis, with abdominal metastasis and the metastatic tumor sites are extracted. The mRNA and protein expression of FABP4 is assessed by RT-qPCR
-
Comp Biochem Physiol B Biochem Mol Biol
Fabp4 contributes toward regulating inflammatory gene expression and oxidative stress in Ctenopharyngodon idella. [Abstract]2022 Apr-May:259:110715. PMID: 34999220 -
Neurosci Lett
Effects of pharmacological inhibition of FABP4 during gestation and lactation on offspring neurodevelopment and behavior. [Abstract]2025 Mar 28:853:138199. PMID: 40090510 -
Parasitol Res
Effects of host fatty acid-binding protein 4 on Eimeria tenella sporozoites invasion of cells. [Abstract]2019 Jun;118(6):1919-1926. PMID: 31069534 -
용액&용해도
DMSO : 175 mg/mL (368.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.38 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sulsky R, et al. Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett. 2007 Jun 15;17(12):3511-5. [Content Brief]
[2]. Lin W, et al. BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase. PLoS One. 2012;7(8):e44570. [Content Brief]
[3]. Lee MY, et al. Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol. 2011 Apr;162(7):1564-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1073 mL | 10.5363 mL | 21.0726 mL | 52.6815 mL |
| 5 mM | 0.4215 mL | 2.1073 mL | 4.2145 mL | 10.5363 mL | |
| 10 mM | 0.2107 mL | 1.0536 mL | 2.1073 mL | 5.2681 mL | |
| 15 mM | 0.1405 mL | 0.7024 mL | 1.4048 mL | 3.5121 mL | |
| 20 mM | 0.1054 mL | 0.5268 mL | 1.0536 mL | 2.6341 mL | |
| 25 mM | 0.0843 mL | 0.4215 mL | 0.8429 mL | 2.1073 mL | |
| 30 mM | 0.0702 mL | 0.3512 mL | 0.7024 mL | 1.7560 mL | |
| 40 mM | 0.0527 mL | 0.2634 mL | 0.5268 mL | 1.3170 mL | |
| 50 mM | 0.0421 mL | 0.2107 mL | 0.4215 mL | 1.0536 mL | |
| 60 mM | 0.0351 mL | 0.1756 mL | 0.3512 mL | 0.8780 mL | |
| 80 mM | 0.0263 mL | 0.1317 mL | 0.2634 mL | 0.6585 mL | |
| 100 mM | 0.0211 mL | 0.1054 mL | 0.2107 mL | 0.5268 mL |